The primary objective of this study is to evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
We are looking for adults with HIV to see if a medicine called tesamorelin can improve physical strength and muscle health when used with exercise. We will also want to see how it impacts people’s lives and see if the benefits last after people stop taking the medicine.
This study will test if adding a new medicine called VIB4920 to regular lupus treatment can help people with lupus nephritis (a kidney problem caused by lupus) feel better. It will also check if this new medicine is safe.
Researchers are testing a drug called IMVT-1402 to see if it is safe and if it helps people with skin lupus (a type called subacute or chronic cutaneous lupus) with or without lupus that affects the whole body.
We are doing this study to see if a medicine called anifrolumab is safe to use in adults with systemic sclerosis. We also want to find out if the medicine helps with disease symptoms and if it stops the disease from getting worse.
This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with cutaneous lupus erythematosus (CLE)
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
This study will look at how well an injectable treatment works for people with detectable levels of HIV who are taking oral antiretroviral therapy (ART). This study will also check if the treatment is safe, how long it lasts, and ask about people’s experience.
We want to find out how well the medicine Belimumab works in real life for adults who have active lupus nephritis. This study also wants to see if belimumab helps keep the kidneys healthy for a long time.
The primary objective of the study is to evaluate the efficacy of switching to oral weekly ISL/LEN tablet regimen versus continuing standard of care in virologically suppressed PWH at Week 48.
We are looking for adults to join a national study to help us learn more about how rheumatoid arthritis (RA) develops.
This study is testing a new drug called SC291 to see if it is safe and if it can help treat serious autoimmune diseases that have come back or stopped responding to treatment.
This study wants to find better treatments for people with autoimmune diseases like rheumatoid arthritis (RA). By studying the different types of cells found in people with RA, researchers can learn more about how RA damages joints.
To evaluate the efficacy of GS-5718 versus placebo-to-match (PTM) in reducing skin disease activity for participants with CLE with or without systemic lupus erythematosus. To evaluate the efficacy of GS-5718 versus PTM in reducing skin disease activity for participants with CLE with or without SLE. To evaluate the safety and tolerability of GS-5178 in participants with CLE with or without SLE.
For Period 1, the primary objective is to evaluate the efficacy and safety of upadacitinib and adalimumab, in adult subjects on background MTX, following an inadequate response or intolerance to a single TNFi. For Period 2, the objective is to evaluate the long-term safety, tolerability, and efficacy of upadacitinib and adalimumab in subjects who have completed Period 1.
In this study, we plan to learn about the causes of rheumatoid arthritis (RA) and about lung disease in RA. RA is an autoimmune disease that can cause arthritis, and in some people, RA can also be related to lung disease called ‘interstitial lung disease’ (or ILD).
This study wants to see if gut problems are worse in HIV+ men that have sex with men that have metabolic syndrome compared those without metabolic syndrome.
To learn more about lung disease and risk of lung disease in early RA.
This study involves chimeric antigen receptor (CAR) T cell therapy, which is a relatively new therapeutic approach that uses a patient's own immune cells to treat their disease. In autoimmune diseases such as rheumatoid arthritis (RA), certain parts of the immune system are overactive, leading to inflammation. A subtype of immune cells, called regulatory T cells (Tregs), normally help to reduce ...
The primary objective of the current study is to validate the performance of the current ASAS classification criteria in a prospective, combined cohort of patients presenting with undiagnosed current back pain.
The primary objective of this study is to demonstrate efficacy of BIIB059 compared with placebo in participants with active systemic lupus erythematosus (SLE), who are receiving background lupus standard of care (SOC) therapy in reducing disease activity.
To find out if bNAbs, VRC07-523LS and PGT121.414.LS, are safe for administration with ART. To evaluate if the bNAbs are effective at keeping HIV from reproducing. It is necessary to stop taking ART after receiving the bNAbs or placebos for bNAbs. This is referred to as an ATI (analytical treatment interruption).
To longitudinally study individuals at risk for spondyloarthritis and spondyloarthritis associated diseases.
The purpose of this study is to determine how the body's immune system interacts with nuts and other foods to cause allergic reaction. This study also plans to validate a test that is being developed to help predict reactions to peanuts.
The study aims to assess safety and tolerability of oral toll-like receptor (TLR) 8 agonist Selgantolimod (SLGN) administered for 24 weeks in participants with both CHB and HIV who have been receiving suppressive antiviral therapy for both viruses for ≥5 years and have qHBsAg level >1000 (3 log10) IU/mL at screening. The study will also evaluate if TLR8 stimulation with SLGN will reduce hepatitis ...
Primary objective is to evaluate the effectiveness of cenerimod 4mg at reducing disease activity compared to placebo. The secondary objective is to evaluate the effect of cenerimod 4mg to control the disease compared to placebo. The safety objective is to evaluate the safety and tolerability of cenerimod 4mg.
To evaluate the safety and tolerability of benralizumab